系统论视角下我国新药研发激励制度进展及对策分析

The Development and Countermeasures of Incentive System for New Medicines R&D in China based on System Theory

新药研发是医药行业供给侧结构改革的重点,激励新药创制可加快医药行业的产业升级,优化资源配置。本文在系统论的视角下,整体分析中国新药研发的激励政策现状,并借鉴美印药品创新激励制度的经验,发现我国在药品全生命周期上已初步形成系列的激励政策,但其政策的具体操作性和完整性还有待加强,我国应该基于国情,积极参与国际合作,从注册审批、上市、专利、定价等多个方面完善配套措施,建立系统科学的可持续的新药研发激励制度。

The R＆D of new medicines is the focus of the supply-side structural reforms in the pharmaceutical industry. Creating the incentives can accelerate the industrial upgrading of the pharmaceutical industry and optimize the allocation of resources. From the perspective of systems theory, this article analyzed the status quo of incentive policies for China＇s new medicines R＆D and learned from the foreign experiences. Then it found that China had formed a series of incentive policies on the entire life cycle of medicines, but the policies＇operability and integrity still needed to be strengthened. It is necessary to improve the supports for all the aspects, such as new medicines＇ registration, approval, patents, pricing, and so on. And we should participate in international cooperation actively and try to establish a scientific and sustainable incentive system for the R＆D of new medicines.